Department of Surgery, Saint Louis University, 3635 Vista at Grand Blvd,, St, Louis, Missouri 63110, USA.
Exp Hematol Oncol. 2013 Nov 8;2(1):30. doi: 10.1186/2162-3619-2-30.
Neoadjuvant therapy is an under-utilized regimen for the treatment of metastatic melanoma. The use of this approach has been increasing in other tumor types. Neoadjuvant therapy may reduce occult circulating tumor cell burden in the face of bulky disease and afford a real time evaluation of treatment effectiveness. Neoadjuvant approach can also provide preoperative histologic and molecular analysis of treated tissue that may guide the postoperative treatment planning in patients with resectable metastatic melanoma lesions. The putative benefits of better margin control and clearance of occult systemic disease would theoretically improve surgical outcome. With the advent of effective agents against metastatic melanoma, this common approach to the treatment of rectal cancer, metastatic colon cancer, and breast cancer should also be evaluated as a viable treatment strategy for advanced stage melanoma.
新辅助治疗是一种治疗转移性黑色素瘤尚未充分利用的方案。这种方法在其他肿瘤类型中的应用正在增加。新辅助治疗可以减少大量疾病中隐匿性循环肿瘤细胞的负担,并提供治疗效果的实时评估。新辅助方法还可以为可切除转移性黑色素瘤病变患者提供治疗组织的术前组织学和分子分析,这可能有助于指导术后治疗计划。更好的边缘控制和清除隐匿性全身疾病的潜在好处理论上可以改善手术结果。随着针对转移性黑色素瘤的有效药物的出现,这种常见的直肠癌、转移性结肠癌和乳腺癌的治疗方法也应该被评估为晚期黑色素瘤的可行治疗策略。